CN114181304A - Anti-influenza A virus antibody, detection kit and preparation method - Google Patents

Abstract

The invention discloses an anti-influenza A virus antibody, a detection kit and a preparation method, and relates to the technical field of antibodies. The anti-influenza a virus antibodies disclosed herein comprise a heavy chain complementarity determining region and a light chain complementarity determining region. The antibody has good affinity to influenza A virus antigen, and has good sensitivity and specificity when used for detecting influenza A virus.

Description

Anti-influenza A virus antibody, detection kit and preparation method

Technical Field

The invention relates to the technical field of antibodies, and particularly relates to an anti-influenza A virus antibody, a detection kit and a preparation method.

Background

Influenza viruses (Flu), referred to as Influenza viruses for short, are representative species of the orthomyxoviridae family, including human Influenza viruses, swine Influenza viruses, equine Influenza viruses, avian Influenza viruses, etc., wherein human Influenza viruses can be classified into three types, i.e., a (a), B (B), and C (C), according to the antigenicity of nucleoprotein thereof, and are pathogens of Influenza. Influenza virus can cause infection and morbidity of various animals such as human, poultry, pigs, horses, bats and the like. The human infectable in the medicine is mainly influenza A virus and influenza B virus, mainly causes the infection of the upper respiratory tract, and also causes the infection of the lower respiratory tract of children and adults, mainly pneumonia, and the severe influenza of infants is often accompanied by bronchus and high fever.

Influenza a viruses (Influenza a, Flu-a) are successfully separated in 1933, antigens of the Influenza a viruses are easy to change, and the Influenza a viruses can be further divided into subtypes such as H1N1, H3N2, H5N1, H7N9 (H represents hemagglutinin of the Influenza virus and N represents neuraminidase of the Influenza virus), which cause pandemics all over the world many times and have a peak every year. The degree of the influenza A virus infection is related to personal immunity, typical symptoms mainly comprise intolerance of cold, persistent high fever and headache, and general symptoms such as sore throat, cough, nasal obstruction, general aching all over the body, hypodynamia and the like are accompanied. The positive detection rate in the circulation period is 20-40% and the positive rate in the non-epidemic season is 2-20% in literature reports. The persistent epidemic of influenza a virus brings great interference and pressure to the public epidemic prevention system of people's health, life and society, and it has become one of the main research objects of epidemiology.

The detection method aiming at the influenza A virus in the market at present mainly comprises a fluorescence PCR method, an immunization method and virus separation culture identification. The fluorescence PCR method is to carry out real-time detection on the PCR process through a fluorescence signal in the PCR amplification process, and aims at qualitative or quantitative detection, and the method is a gold standard for pathogen detection; the immunization method is to detect target protein by specific binding of antigen and antibody; the virus isolation and culture method is usually chicken embryo inoculation, animal inoculation, tissue (cell) culture and the like, and the generated results are observed and analyzed. Although the fluorescence PCR method has better sensitivity and specificity, the detection window period is shorter, the time is strived for early diagnosis and early treatment of epidemic diseases, reduction of mortality and control of epidemic situations, and the fluorescence PCR method can be used as a gold standard for diagnosis. However, the method has high requirements on detection personnel, needs professional skill training, and can be used for diagnosis and detection only by using professional instruments and equipment in qualified professional laboratories, so the method is not suitable for quick diagnosis of clinical or epidemic disease monitoring lines. The virus isolation culture identification has long time consumption, high environmental requirement, large infection risk of operators, poor culture effect and very limited application in the aspects of clinical diagnosis, epidemic disease monitoring and the like. The immunoassay detection reagent aims at antigen or antibody in a sample, has high detection speed and high accuracy, has low requirements on laboratories and operators, is generally suitable for primary screening of clinical laboratories of hospitals, disease control system laboratories and the like, and has very important functions on initial detection of influenza A, successful outbreak control in hospitals and communities and guidance of treatment.

Currently, immunodiagnostic reagent products for influenza a on the market mainly include enzyme-linked immunosorbent assay (ELISA method), colloidal gold immunochromatography, such as influenza a virus antigen detection reagent of guangzhou boil (colloidal gold method), R & D influenza a ELISA kit, and the like. In the above diagnostic reagent products, specific antibodies against influenza a virus are required, and the specific antibodies against influenza a virus on the market have certain defects in specificity and sensitivity.

In view of this, the invention is particularly proposed.

Disclosure of Invention

The invention aims to provide an anti-influenza A virus antibody, a detection kit and a preparation method thereof, wherein the antibody has good affinity to an influenza A virus antigen, and the antibody has good sensitivity and specificity when used for detecting the influenza A virus.

The invention is realized by the following steps:

in one aspect, the invention provides an anti-influenza a virus antibody or functional fragment thereof having the following complementarity determining regions:

CDR-VH 1: G-F-S-X1-T-A-X2-G-X3-H, wherein: x1 is I or L; x2 is F or Y; x3 is L, V or I;

CDR-VH 2: X1-W-X2-G-G-S-T-N-Y-N-X3-T-X4-M-S, wherein: x1 is LL, LI, II or IL; x2 is G or A; x3 is P or A; x4 is L or Y;

CDR-VH 3: A-X1-E-X2-T-G-R-M, wherein: x1 is K or R; x2 is L, V or I;

CDR-VL 1: K-A-S-Q-D-X1-N-X2-Y-X3-S, wherein: x1 is I or L; x2 is Q, R or N; x3 is I, V or L;

CDR-VL 2: R-A-N-R-X1-X2-D, wherein: x1 is I or L; x2 is I, V or L;

CDR-VL 3: X1-Q-Y-X2-E-F-P-Y, wherein: x1 is I, V or L; x2 is N or D.

The anti-influenza A virus antibody or the functional fragment thereof provided by the invention has the complementarity determining region structure, the complementarity determining region structure can ensure that the antibody or the functional fragment thereof can be specifically combined with an influenza A virus antigen and has better affinity to the influenza A virus antigen, and the antibody or the functional fragment thereof has better specificity and sensitivity when being used for detecting the influenza A virus.

In an alternative embodiment of the method of the present invention,

in CDR-VH1, X2 is F;

in CDR-VH2, X2 is A;

in CDR-VH3, X1 is R;

in CDR-VL1, X1 is I;

in CDR-VL2, X1 is L;

in CDR-VL3, X2 is D.

The present inventors have found that when the mutation site in each complementarity determining region is the amino acid residue, the antibody exhibits better affinity for influenza a virus.

In an alternative embodiment, in CDR-VH1, X1 is I.

In an alternative embodiment, in CDR-VH1, X1 is L.

In an alternative embodiment, in CDR-VH1, X3 is L.

In alternative embodiments, in CDR-VH1, X3 is V.

In an alternative embodiment, in CDR-VH1, X3 is I.

In an alternative embodiment, in CDR-VH2, X1 is LL.

In alternative embodiments, in CDR-VH2, X1 is LI.

In alternative embodiments, in CDR-VH2, X1 is II.

In alternative embodiments, in CDR-VH2, X1 is IL.

In an alternative embodiment, in CDR-VH2, X3 is P.

In alternative embodiments, in CDR-VH2, X3 is a.

In an alternative embodiment, in CDR-VH2, X4 is L.

In alternative embodiments, in CDR-VH2, X4 is Y.

In an alternative embodiment, in CDR-VH3, X2 is L.

In alternative embodiments, in CDR-VH3, X2 is V.

In an alternative embodiment, in CDR-VH3, X2 is I.

In an alternative embodiment, in CDR-VL1, X2 is Q.

In an alternative embodiment, in CDR-VL1, X2 is R.

In an alternative embodiment, in CDR-VL1, X2 is N.

In an alternative embodiment, in CDR-VL1, X3 is I.

In an alternative embodiment, in CDR-VL1, X3 is V.

In an alternative embodiment, in CDR-VL1, X3 is L.

In an alternative embodiment, in CDR-VL2, X2 is I.

In an alternative embodiment, in CDR-VL2, X2 is V.

In an alternative embodiment, in CDR-VL2, X2 is L.

In an alternative embodiment, in CDR-VL3, X1 is I.

In an alternative embodiment, in CDR-VL3, X1 is V.

In an alternative embodiment, in CDR-VL3, X1 is L.

In alternative embodiments, each complementarity determining region of the antibody, or functional fragment thereof, is selected from any one of the following combinations of mutations 1-62:

in alternative embodiments, the antibody or functional fragment thereof binds influenza a virus with K_D≤4.4×10^{- 8}Affinity binding in mol/L.

In an alternative embodiment, K_D≤4×10^-8mol/L, or K_D≤3×10^-8mol/L, or K_D≤2×10^-8mol/L, or K_D≤1×10^-8mol/L, or K_D≤9×10^-9mol/L, or K_D≤8×10^-9mol/L, or K_D≤7×10^-9mol/L, or K_D≤6×10^-9mol/L, or K_D≤5×10^-9mol/L, or K_D≤4×10^-9mol/L, or K_D≤3×10^-9mol/L, or K_D≤2×10^-9mol/L。

In an alternative embodiment, 2.08 × 10^-9mol/L≤K_D≤8.47×10^-9mol/L。

K_DThe detection of (2) is carried out with reference to the method in the examples of the present invention.

In an alternative embodiment of the method of the present invention,

in CDR-VH1, X2 is Y;

in CDR-VH2, X2 is G;

in CDR-VH3, X1 is K;

in CDR-VL1, X1 is L;

in CDR-VL2, X1 is I;

in CDR-VL3, X2 is N.

In alternative embodiments, each complementarity determining region of the antibody or functional fragment thereof is selected from any one of the following combinations of mutations 63-70:

in alternative embodiments, the antibody comprises the light chain framework regions FR1-L, FR2-L, FR3-L and FR4-L in sequence as set forth in SEQ ID NOS: 1-4, and/or the heavy chain framework regions FR1-H, FR2-H, FR3-H and FR4-H in sequence as set forth in SEQ ID NOS: 5-8.

In general, the variable regions of the heavy chain (VH) and light chain (VL) can be obtained by linking the CDRs and FRs numbered below in a combined arrangement as follows: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR 4.

It is noted that in other embodiments, each framework region amino acid sequence of an antibody or functional fragment thereof provided herein can have at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% homology to the corresponding framework region described above (SEQ ID NO:1, 2, 3, 4, 5, 6, 7, or 8).

In alternative embodiments, the antibody further comprises a constant region.

In alternative embodiments, the constant region is selected from the constant regions of any one of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, and IgD.

In alternative embodiments, the species of the constant region is derived from a cow, horse, dairy cow, pig, sheep, goat, rat, mouse, dog, cat, rabbit, camel, donkey, deer, mink, chicken, duck, goose, turkey, chicken fountains, or human.

In alternative embodiments, the constant region is derived from a mouse.

In alternative embodiments, the light chain constant region sequence of the constant region is set forth in SEQ ID NO. 9 and the heavy chain constant region sequence of the constant region is set forth in SEQ ID NO. 10.

In alternative embodiments, the functional fragment is selected from any one of VHH, F (ab ') 2, Fab', Fab, Fv and scFv of the antibody.

Functional fragments of the above antibodies typically have the same binding specificity as the antibody from which they are derived. It will be readily understood by those skilled in the art from the disclosure of the present invention that functional fragments of the above antibodies can be obtained by methods such as enzymatic digestion (including pepsin or papain) and/or by chemical reduction cleavage of disulfide bonds. Based on the disclosure of the structure of the intact antibody, the above-described functional fragments are readily available to those skilled in the art.

Functional fragments of the above antibodies can also be obtained by recombinant genetic techniques also known to those skilled in the art or synthesized by, for example, automated peptide synthesizers, such as those sold by Applied BioSystems and the like.

In another aspect, the present invention provides a reagent or a kit for detecting influenza a virus, comprising the antibody or the functional fragment thereof according to any one of the above.

In an alternative embodiment, the antibody or functional fragment thereof in the above-described reagent or kit is labeled with a detectable label.

Detectable labels are substances having properties, such as luminescence, color development, radioactivity, etc., which can be observed directly by the naked eye or detected by an instrument, by which qualitative or quantitative detection of the respective target substance can be achieved.

In alternative embodiments, the detectable labels include, but are not limited to, fluorescent dyes, enzymes that catalyze the development of a substrate, radioisotopes, chemiluminescent reagents, and nanoparticle-based labels.

In the actual use process, one skilled in the art can select a suitable marker according to the detection condition or actual requirement, and whatever marker is used belongs to the protection scope of the present invention.

In alternative embodiments, the fluorescent dyes include, but are not limited to, fluorescein-based dyes and derivatives thereof (e.g., including, but not limited to, Fluorescein Isothiocyanate (FITC) hydroxyphoton (FAM), tetrachlorofluorescein (TET), etc. or analogs thereof), rhodamine-based dyes and derivatives thereof (e.g., including, but not limited to, red Rhodamine (RBITC), Tetramethylrhodamine (TAMRA), rhodamine b (tritc), etc. or analogs thereof), Cy-series dyes and derivatives thereof (e.g., including, but not limited to, Cy2, Cy3, Cy3B, Cy3.5, Cy5, Cy5.5, Cy3, etc. or analogs thereof), Alexa-series dyes and derivatives thereof (e.g., including, but not limited to, Alexa fluor350, 405, 430, 488, 532, 546, 555, 568, 594, 610, 33, 647, 680, 700, 750, etc. or analogs thereof), and protein-based dyes and derivatives thereof (e.g., including, but not limited to, Phycoerythrin (PE), Phycocyanin (PC), phycocyanin (e.g., including, pyrenochrome, and analogs thereof), Allophycocyanin (APC), polymethacrylic flavin-chlorophyll protein (precP), etc.).

In alternative embodiments, the enzyme that catalyzes the color development of the substrate includes, but is not limited to, horseradish peroxidase, alkaline phosphatase, beta-galactosidase, glucose oxidase, carbonic anhydrase, acetylcholinesterase, and glucose-6-phosphate deoxyenzyme.

In alternative embodiments, the radioisotope includes, but is not limited to²¹²Bi、¹³¹I、¹¹¹In、⁹⁰Y、¹⁸⁶Re、²¹¹At、¹²⁵I、¹⁸⁸Re、¹⁵³Sm、²¹³Bi、³²P、⁹⁴mTc、⁹⁹mTc、²⁰³Pb、⁶⁷Ga、⁶⁸Ga、⁴³Sc、⁴⁷Sc、¹¹⁰mIn、⁹⁷Ru、⁶²Cu、⁶⁴Cu、⁶⁷Cu、⁶⁸Cu、⁸⁶Y、⁸⁸Y、¹²¹Sn、¹⁶¹Tb、¹⁶⁶Ho、¹⁰⁵Rh、¹⁷⁷Lu、¹⁷²Lu and¹⁸F。

in alternative embodiments, the chemiluminescent reagent includes, but is not limited to, luminol and its derivatives, lucigenin, crustacean fluorescein and its derivatives, bipyridyl ruthenium and its derivatives, acridinium ester and its derivatives, dioxane and its derivatives, lotrine and its derivatives, and peroxyoxalate and its derivatives.

In alternative embodiments, the nanoparticle-based labels include, but are not limited to, nanoparticles, colloids, organic nanoparticles, magnetic nanoparticles, quantum dot nanoparticles, and rare earth complex nanoparticles.

In alternative embodiments, the colloid includes, but is not limited to, colloidal metals, disperse dyes, dye-labeled microspheres, and latex.

In alternative embodiments, the colloidal metals include, but are not limited to, colloidal gold, colloidal silver, and colloidal selenium.

In another aspect, the present invention provides a nucleic acid molecule encoding the above antibody or functional fragment thereof.

In another aspect, the invention provides a vector comprising the nucleic acid molecule described above.

In another aspect, the present invention provides a recombinant cell comprising the vector described above.

In another aspect, the present invention provides a method of preparing an antibody or functional fragment thereof, comprising: culturing the recombinant cell as described above, and separating and purifying the antibody or functional fragment thereof from the culture product.

Based on the disclosure of the amino acid sequence of the antibody or its functional fragment, it is easy for those skilled in the art to think that the antibody or its functional fragment can be prepared by genetic engineering techniques or other techniques (chemical synthesis, hybridoma cells), for example, by separating and purifying the antibody or its functional fragment from the culture product of recombinant cells capable of recombinantly expressing the antibody or its functional fragment as described above, and this is within the scope of the present invention, regardless of the technique used to prepare the antibody or its functional fragment.

Drawings

In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings needed to be used in the embodiments will be briefly described below, it should be understood that the following drawings only illustrate some embodiments of the present invention and therefore should not be considered as limiting the scope, and for those skilled in the art, other related drawings can be obtained according to the drawings without inventive efforts.

FIG. 1 is the result of reducing SDS-PAGE of the anti-influenza A virus antibody of example 1.

Detailed Description

In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the formulations or unit dosages herein, some are now described. Unless otherwise indicated, the techniques employed or contemplated herein are standard methods. The materials, methods, and examples are illustrative only and not intended to be limiting.

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, molecular biology (including recombinant techniques), microbiology, biochemistry and immunology, which are within the skill of the art. Such techniques are well explained in the literature, e.g. "molecular cloning: a Laboratory Manual, second edition (Sambrook et al, 1989); oligonucleotide Synthesis (oligo Synthesis) (eds. m.j. goal, 1984); animal Cell Culture (Animal Cell Culture), ed.r.i. freshney, 1987; methods in Enzymology (Methods in Enzymology), Handbook of Experimental Immunology (Handbook of Experimental Immunology) (ed. D.M.Weir and C.C.Black well), Gene Transfer Vectors for Mammalian Cells (ed. J.M.Miller and M.P.Calos) (ed. J.M.and M.P.Calos) (ed. 1987), Methods in Current Generation (Current Protocols in Molecular Biology) (ed. F.M.Ausubel.et al, 1987), PCR, Polymerase Chain Reaction (ed. PCR: The Polymerase Chain Reaction) (ed. Mullis et al, 1994), and Methods in Current Immunology (ed. J.1991).

The features and properties of the present invention are described in further detail below with reference to examples.

Example 1

Restriction enzyme, Prime Star DNA polymerase, was purchased from Takara in this example. MagExtractor-RNA extraction kit was purchased from TOYOBO. BD SMART^TMRACE cDNA Amplification Kit was purchased from Takara. pMD-18T vector was purchased from Takara. Plasmid extraction kits were purchased from Tiangen corporation. Primer synthesis and gene sequencing were performed by Invitrogen corporation.

1 construction of recombinant plasmid

(1) Antibody Gene preparation

mRNA is extracted from a hybridoma cell strain (4G2) secreting anti-influenza A virus antigen antibody, a DNA product is obtained by an RT-PCR method, the product is added with A by rTaq DNA polymerase for reaction and then inserted into a pMD-18T vector, the product is transformed into DH5 alpha competent cells, and after colonies grow out, 4 clones of the Heavy Chain and Light Chain gene clones are respectively taken and sent to a gene sequencing company for sequencing.

(2) Sequence analysis of antibody variable region genes

Putting the gene sequence obtained by sequencing in an IMGT antibody database for analysis, and analyzing by using VNTI11.5 software to determine that the genes amplified by the heavy Chain primer pair and the Light Chain primer pair are correct, wherein in the gene fragment amplified by the Light Chain, the VL gene sequence is 321bp, belongs to VkII gene family, and a leader peptide sequence of 57bp is arranged in front of the VL gene sequence; in the gene fragment amplified by the Heavy Chain primer pair, the VH gene sequence is 348bp, belongs to a VH1 gene family, and has a leader peptide sequence of 57bp in front.

(3) Construction of recombinant antibody expression plasmid

pcDNA^TM 3.4

vector is a constructed recombinant antibody eukaryotic expression vector, and multiple cloning enzyme cutting sites such as HindIII, BamHI, EcoRI and the like are introduced into the expression vector and named as pcDNA3.4A expression vector, and the vector is called as 3.4A expression vector for short in the following; according to the sequencing result of the antibody variable region gene in the pMD-18T, VL and VH gene specific primers of the antibody are designed, two ends of the primers are respectively provided with HindIII and EcoRI restriction sites and protective bases, and a Light Chain gene fragment of 0.73kb and a Heavy Chain gene fragment of 1.43kb are amplified by a PCR amplification method.

The gene fragments of the Heavy Chain and the Light Chain are subjected to double enzyme digestion by HindIII/EcoRI respectively, the 3.4A vector is subjected to double enzyme digestion by HindIII/EcoRI, the Heavy Chain gene and the Light Chain gene are respectively connected into the 3.4A expression vector after the fragments and the vector are purified and recovered, and recombinant expression plasmids of the Heavy Chain and the Light Chain are respectively obtained.

2 Stable cell line selection

(1) Transient transfection of recombinant antibody expression plasmid into CHO cells and determination of expression plasmid activity

Plasmid was diluted to 400ng/ml with ultrapure water and CHO cells were conditioned at 1.43X 10⁷cells/ml are put into a centrifuge tube, 100 mul of plasmid is mixed with 700 mul of cells, the mixture is transferred into an electric rotating cup and is electrically rotated, the sampling counting is carried out on 3 rd, 5 th and 7 th days, and the sampling detection is carried out on 7 th day.

Coating liquid (main component NaHCO)₃) Diluting goat anti-mouse IgG 1ug/ml for micronisationCoating the plate with 100 μ l/well at 4 deg.C overnight; the next day, washing liquid (main component Na)₂HPO₄+ NaCl) for 2 times, patting dry; adding blocking solution (20% BSA + 80% PBS), beating to dry at 37 deg.C for 1 hr, and adding blocking solution (120 μ l per well); adding diluted cell supernatant at a concentration of 100 μ l/well at 37 deg.C for 60 min; throwing off liquid in the plate, patting dry, adding 20% mouse negative blood, sealing, and sealing at 37 ℃ for 1h, wherein each hole is 120 mu l; throwing off the liquid in the plate, patting dry, adding diluted influenza A antigen 100 mul per hole, 37 ℃, 40 min; washing with washing solution for 5 times, and drying; adding 100 mul of influenza A monoclonal antibody marked with HRP into each hole, and performing temperature control at 37 ℃ for 30 min; adding a developing solution A (50 μ l/hole), adding a developing solution B (50 μ l/hole), and standing for 10 min; adding stop solution into the mixture, wherein the concentration of the stop solution is 50 mu l/hole; OD readings were taken at 450nm (reference 630nm) on the microplate reader. The results show that the reaction OD after the cell supernatant is diluted 1000 times is still larger than 1.0, and the reaction OD of the wells without the cell supernatant is smaller than 0.1, which indicates that the antibody generated after the plasmid is transiently transformed has activity on the influenza A antigen.

(2) Linearization of recombinant antibody expression plasmids

The following reagents were prepared: 50 mul Buffer, 100 ug/tube DNA, 10 mul Puv I enzyme, supplementing 500 mul sterile water, and enzyme cutting overnight in 37 deg.C water bath; sequentially extracting with equal volume of phenol/chloroform/isoamyl alcohol (lower layer) 25:24:1 and then chloroform (water phase); precipitating with 0.1 volume (water phase) of 3M sodium acetate and 2 volumes of ethanol on ice, rinsing with 70% ethanol, removing organic solvent, re-melting with appropriate amount of sterilized water after ethanol is completely volatilized, and finally measuring concentration.

(3) Stable transfection of recombinant antibody expression plasmid, pressurized screening of stable cell lines

Plasmid was diluted to 400ng/ml with ultrapure water and CHO cells were conditioned at 1.43X 10⁷cells/ml are put into a centrifuge tube, 100 mul of plasmid is mixed with 700 mul of cells, and the mixture is transferred into an electric rotating cup and is electrically rotated, and the next day is counted; 25umol/L MSX 96-well pressure culture for about 25 days.

Observing the marked clone holes with cells under a microscope, and recording the confluence degree; taking culture supernatant, and sending the culture supernatant to a sample for detection; selecting cell strains with high antibody concentration and relative concentration, transferring the cell strains into 24 holes, and transferring the cell strains into 6 holes after 3 days; after 3 days, the seeds were kept and cultured in batches, and the cell density was adjusted to 0.5X 10⁶cells/ml, 2.2mlBatch culture with cell density of 0.3X 10⁶cell/ml, 2ml for seed preservation; and (4) 7 days, carrying out batch culture supernatant sample sending detection in 6 holes, and selecting cell strains with small antibody concentration and cell diameter to transfer TPP for seed preservation and passage.

3 recombinant antibody production

(1) Cell expanding culture

After the cells are recovered, the cells are cultured in a shaking flask with the specification of 125ml, the inoculation volume is 30ml, the culture medium is 100% Dynamis culture medium, and the cells are placed in a shaking table with the rotation speed of 120r/min, the temperature of 37 ℃ and the carbon dioxide of 8%. Culturing for 72h, inoculating and expanding culture at an inoculation density of 50 ten thousand cells/ml, wherein the expanding culture volume is calculated according to production requirements, and the culture medium is 100% Dynamis culture medium. Then the culture is expanded every 72 h. When the cell amount meets the production requirement, the production is carried out by strictly controlling the inoculation density to be about 50 ten thousand cells/ml.

(2) Shake flask production and purification

Shake flask parameters: the rotating speed is 120r/min, the temperature is 37 ℃, and the carbon dioxide is 8 percent. Feeding in a flowing mode: daily feeding was started when the culture was carried out for 72h in a shake flask, 3% of the initial culture volume was fed daily to HyCloneTM Cell BoostTM Feed 7a, and one thousandth of the initial culture volume was fed daily to Feed 7b, up to day 12 (day 12 feeding). Glucose was supplemented with 3g/L on the sixth day. Samples were collected on day 13. Affinity purification was performed using a proteinA affinity column. Mu.g of the purified antibody was subjected to reducing SDS-PAGE, and 4. mu.g of an external control antibody was used as a control, and the electrophorogram shown in FIG. 1 showed two bands, one of which showed 50KD (heavy chain, SEQ ID NO.14) and the other of which showed 28KD (light chain, SEQ ID NO.13) after reducing SDS-PAGE.

Example 2

Detection of antibody Performance

(1) Example 1 Activity assay of antibodies and mutants thereof

Analysis of the antibody (WT) sequence of example 1 showed that the heavy chain variable region is represented by SEQ ID NO:12, wherein the amino acid sequence of each complementarity determining region in the heavy chain variable region is as follows:

CDR-VH1：G-F-S-I(X1)-T-A-Y(X2)-G-L(X3)-H；

CDR-VH2：LI(X1)-W-G(X2)-G-G-S-T-N-Y-N-A(X3)-T-L(X4)-M-S；

CDR-VH3：A-K(X1)-E-V(X2)-T-G-R-M；

the light chain variable region is shown as SEQ ID NO:11, wherein the amino acid sequences of the complementarity determining regions on the light chain variable region are as follows:

CDR1-VL：K-A-S-Q-D-L(X1)-N-Q(X2)-Y-I(X3)-S；

CDR-VL2：R-A-N-R-I(X1)-L(X2)-D；

CDR-VL3：I(X1)-Q-Y-N(X2)-E-F-P-Y。

based on the anti-influenza a virus antibody (WT) of example 1, mutations were made in the complementarity determining regions at sites relevant for antibody activity, wherein X1, X2, X3, and X4 were all mutated sites. See table 1 below.

TABLE 1 mutant sites associated with antibody Activity

Antibody binding activity assay in table 1:

coating liquid (main component NaHCO)₃) Diluting goat anti-mouse IgG1 mug/ml for coating a microplate, wherein each well is 100 mug, and the temperature is 4 ℃ overnight; the next day, washing liquid (main component Na)₂HPO₄+ NaCl) for 2 times, patting dry; adding blocking solution (20% BSA + 80% PBS), beating to dry at 37 deg.C for 1 hr, and adding blocking solution (120 μ l per well); adding the diluted purified antibody in the table 1, 100 mul/hole, 37 ℃, 60 min; throwing off liquid in the plate, patting dry, adding 20% mouse negative blood, sealing, and sealing at 37 ℃ for 1h, wherein each hole is 120 mu l; throwing off the liquid in the plate, patting dry, adding diluted influenza A antigen 100 mul per hole, 37 ℃, 40 min; washing with washing solution for 5 times, and drying; adding HRP-labeled influenza A monoclonal antibody (obtained from Fipeng Bio Inc) at 37 deg.C for 30min in a volume of 100. mu.l per well; adding color development liquid A (50 μ L/well containing 2.1g/L citric acid, 12.25g/L citric acid, 0.07g/L acetanilide and 0.5g/L carbamide peroxide) and adding color development liquid B (50 μ L/well containing 1.05g/L citric acid, 0.186g/L LEDTA.2Na, 0.45g/L TMB and 0.2ml/L concentrated HCl) for 10 min; add stop solution (50. mu.l/well, 0.75 g/EDTA-2)Na and 10.2ml/L concentrated H₂SO₄) (ii) a OD readings were taken at 450nm (reference 630nm) on the microplate reader. The results are shown in Table 2 below.

TABLE 2 Activity data of WT antibodies and mutants thereof

Antibody concentration (ng/ml)	200	25	12.5	6.250	3.125	0
							WT	2.089	1.339	0.972	0.466	0.121	0.073
Mutation 1	2.256	1.655	1.113	0.673	0.379	0.072
							Mutation 2	2.129	1.645	1.085	0.64	0.339	0.082
Mutation 3	2.126	1.631	1.107	0.691	0.398	0.071
							Mutation 4	2.114	1.62	1.148	0.688	0.301	0.077
Mutation 5	0.564	0.326	0.072	-	-	-
							Mutation 6	0.693	0.395	0.06	-	-	-
Mutation 7	0.633	0.316	0.075	-	-	-

As can be seen from the results in Table 2, WT, as well as mutant 1-mutant 4 antibodies had better binding activity, with mutant 1 having the best binding activity and mutant 5-mutant 7 having essentially no binding activity.

(2) Affinity detection of antibodies and mutants thereof (a) mutations were made at other sites based on mutation 1, and the sequences of each mutation are shown in table 3 below.

TABLE 3 mutation sites related to antibody affinity

Affinity assay

Using AMC sensors, purified antibodies were diluted to 10ug/ml with PBST, influenza a antigen was diluted with PBST in a gradient: 20ug/ml, 6.66ug/ml, 2.22ug/ml, 0.74ug/ml, 0.24ug/ml, 0.082ug/ml, 0.027ug/ml, 0.0091 ug/ml;

the operation flow is as follows: equilibration for 60s in buffer 1(PBST), immobilization of antibody in solution for 300s, incubation in buffer 2(PBST) for 180s, binding in antigen solution for 420s, dissociation in buffer 2 for 1200s, and incubation with 10mM GLY solution pH 1.69 and buffer 3And regenerating the sensor and outputting data. K_DIndicating the equilibrium dissociation constant, i.e. affinity. The results are shown in Table 4 below.

Table 4 affinity assay data

As can be seen from the data in Table 3, the antibody obtained by mutation 1 and the antibody obtained by mutation based on the mutation (mutation 1-1 to mutation 1-61) have better affinity; it is demonstrated that the antibodies obtained by mutation in the manner shown in Table 2 on the basis of mutation 1 all have good affinity.

(b) Based on WT, mutation is carried out on other sites, and the affinity of each mutant is detected, the sequence of each mutation is shown in Table 5, and the corresponding affinity data is shown in Table 6.

TABLE 5 mutations with WT as backbone

TABLE 6 affinity assay results for WT antibodies and their mutants

	KD(M)
		WT	4.40E-08
WT 1	2.93E-08
		WT 2	2.77E-08
WT 3	3.17E-08
		WT 4	3.65E-08
WT5	2.87E-08
		WT6	3.73E-08
WT7	3.25E-08

The data in Table 6 show that WT and its mutant (WT1-WT7) also have good affinity, indicating that based on WT, antibodies mutated in the manner shown in Table 5 have good affinity.

(3) Evaluation of stability against naked antibody

Placing the antibody in a temperature range of 4 ℃ (refrigerator), -80 ℃ (refrigerator) and 37 ℃ (thermostat) for 21 days, taking samples in 7 days, 14 days and 21 days for state observation, and performing activity detection on the samples in 21 days, wherein the result shows that under three examination conditions, no obvious protein state change is seen in 21 days of placing the antibody, and the activity does not show a descending trend along with the rise of the examination temperature, which indicates that the antibody is stable. The following table 7 shows the OD results of the enzyme immunity activity assay for 21 days of the mutation 1 antibody test.

TABLE 7

Sample concentration (ng/ml)	200	12.5	0
				Samples at 4 ℃ for 21 days	2.199	1.156	0.053
21 days samples at-80 deg.C	2.211	1.124	0.051
				21 day samples at 37 deg.C	2.208	1.197	0.051

Example 3

Application of antibody in colloidal gold detection

1 preparation of colloidal gold test paper

(1) Preparation of nitrocellulose membranes

Preparation of coating buffer: coating buffer solution containing 6% methanol and 0.01M buffer solution of pH7.2PBS, filtering with 0.22 μ M membrane, standing at 4 deg.C for one week. 1000ml0.01M pH7.2PBS buffer formulation in 6% methanol: NaCl 8g, KCl 0.2g, Na₂HPO₄·12H₂O 2.9g、KH₂PO₄0.2g, 60ml of methanol and double distilled deionized water to reach the volume of 1000 ml.

Preparation of nitrocellulose membrane: diluting the purified antibody to 1-5 mg/ml by using a coating buffer solution, adjusting a machine, and marking a T line as a detection line, wherein the T line is close to the end of the gold label pad and is about 5mm away from the end of the gold label pad; diluting the goat anti-mouse IgG antibody to 1-5 mg/ml by using a coating buffer solution, adjusting a machine, and marking to form a C line, namely a control line, wherein the C line is close to the absorption pad and is about 3mm away from the absorption pad. The distance between the two lines is 5-8 mm and is uniform. Drying at 37 ℃, and packaging for later use.

(2) Preparation of colloidal gold and gold-labeled monoclonal antibody

(a) Preparation of the solution

Preparing chloroauric acid: dissolving chloroauric acid with double distilled deionized water to prepare 1% solution, standing at 4 deg.C for use, and having validity period of four months. 1000ml of 1% chloroauric acid solution formula: 10g of chloroauric acid: double distilled deionized water to 1000 ml.

Preparing trisodium citrate: dissolving sodium citrate with double distilled deionized water to obtain 1% solution, filtering with 0.22 μm membrane, standing for 4 deg.C, and storing for 1000 ml.

Preparation of 0.1M potassium carbonate: prepared by double distilled deionized water, filtered by a 0.22 mu m membrane, and placed at 4 ℃ for standby, and the validity period is four months. 1000ml of 0.1M potassium carbonate solution formulation: 13.8g of potassium carbonate; double distilled deionized water to 1000 ml.

Fourthly, preparing 2 percent PEG-20000: prepared by double distilled deionized water, filtered by a 0.22 mu m membrane, and placed at 4 ℃ for standby, and the validity period is four months. 1000ml 2% PEG-20000 solution formulation: 20g PEG-20000; double distilled deionized water to 1000 ml.

Preparing a marking washing preservation solution: 2% Bovine Serum Albumin (BSA), 0.05% sodium azide (NaN3), 0.01M PBS solution (pH7.2), 0.22 μmembrane filtration, placed at 4 ℃ for use, the effective period of four months. 1000ml mark washing preservation solution formula: 20g BSA, 0.5g NaN3, 0.01M pH7.2PBS solution to volume to 1000 ml.

(b) And (5) preparing colloidal gold.

Diluting 1% chloroauric acid to 0.01% with double distilled deionized water, boiling in electric furnace, adding 2ml 1% trisodium citrate per 100ml 0.01% chloroauric acid, boiling until the liquid is bright red, stopping heating, cooling to room temperature, and supplementing water. The prepared colloidal gold has the advantages of pure appearance, transparency, no sediment or floating matter and one week of validity.

(c) Preparing colloidal gold labeled antibody.

Adjusting the pH value of the colloidal gold to 8.2 by using 0.1M potassium carbonate, adding a labeled strain influenza A antibody (obtained from Ficron organisms) into the colloidal gold according to the ratio of 8-10 mu g antibody/ml, uniformly mixing for 30min by using a magnetic stirrer, adding BSA (bovine serum albumin) until the final concentration is 1%, and standing for 1 hour. Centrifuging at 13000rpm and 4 ℃ for 30min, discarding the supernatant, washing the precipitate twice with a labeled washing and preserving solution, resuspending the precipitate with the labeled washing and preserving solution with one tenth of the initial volume of the colloidal gold, standing at 4 ℃ for later use, and keeping the validity period for one week.

(3) Preparation of gold label pad

(a) And (4) preparing a sealing liquid.

Contains 2% BSA, 0.1% TritonX-100, 0.05% NaN₃0.01M PBS solution with pH7.2, 0.22 μ M membrane filtration, standing at 4 deg.C for use, and effective period of four months. 1000ml of sealing liquid formula: 20g BSA, 0.5g NaN3, 1ml TritonX-100, 0.01M pH7.2PBS solution to 1000 ml.

(b) Preparation of gold label pad

Soaking the gold label pad in the sealing solution for 30min, and oven drying at 37 deg.C. Then, the prepared gold-labeled antibody is evenly spread on a gold-labeled pad, each milliliter of solution is spread by 20 square centimeters, and the gold-labeled pad is frozen, dried, packaged and placed at 4 ℃ for later use.

(4) Preparation of test paper strip sample pad

(a) And (4) preparing a sealing liquid.

Contains 2% BSA, 0.1% TrtioX-100, 0.05% NaN₃0.01M PBS solution with pH7.2, 0.22 μ M membrane filtration, standing for 4 degrees for use, and validity period of four months. 1000ml of sealing liquid formula: 20g BSA, 0.5g NaN₃1ml of TrtioX-100 and 0.01M PBS solution with pH7.2 are added to make the volume reach 1000 ml.

(b) Preparation of sample pad.

Soaking the sample pad in sealing solution for 30min, oven drying at 37 deg.C, packaging, and standing at 4 deg.C.

(5) Assembly of test paper

Absorbent pads (available from Millipore corporation), nitrocellulose membranes, gold-labeled pads, and sample pads were placed on a non-absorbent support sheet and cut into 3mm wide strips. And packaging every ten small strips with one bag, adding a drying agent, and performing vacuum packaging to obtain the colloidal gold test paper for detecting the influenza A virus.

2 application of antibody in colloidal gold detection

The test strip assembled as described above was used to detect whether or not the test material contained influenza A virus antigen, thereby determining the activity of the antibody obtained in the above example on detection of influenza A virus antigen. Whether or not the test material contains an influenza A virus antigen is detected by a double antibody sandwich method. During detection, the influenza A virus antigen is combined with the influenza A antibody originally marked by the colloidal gold to form an influenza A antigen-colloidal gold mark-influenza A antibody compound, the influenza A antigen-colloidal gold mark-influenza A antibody compound swims forwards along the nitrocellulose membrane due to capillary action, and when the influenza A antigen-colloidal gold mark-influenza A antibody compound reaches a detection line, the influenza A antigen-colloidal gold mark-influenza A antibody compound is combined with the influenza A antibody obtained in the embodiment to form an influenza A antibody-influenza A antigen-colloidal gold mark-influenza A antibody compound, so that the influenza A antibody-influenza A antigen-colloidal gold mark-influenza A antibody compound is enriched on the detection line, and a red precipitation line is formed. The influenza A antigen-colloidal gold labeled-influenza A antibody compound which is not combined with the influenza A antibody on the detection line is captured by the goat anti-mouse IgG antibody through the detection line and is enriched on the quality control line to form a red precipitation line. And judging as a positive result when the detection line and the quality control line have the red precipitation line at the same time. If the sample does not contain the influenza A virus antigen, when the colloidal gold-labeled influenza A antibody which is not combined with the influenza A virus antigen reaches the detection line, a compound of the influenza A antibody-influenza A antigen-colloidal gold-labeled influenza A antibody cannot be formed, and the colloidal gold-labeled influenza A antibody compound which is not combined with the influenza A antigen passes through the detection line and is only enriched on the quality control line to form a red precipitation line, and the result is judged to be negative.

The results are shown in Table 8 below.

TABLE 8

Remarking: the gold mark color development is formed by adding a number C, and the smaller the number behind the number C is, the stronger the color development is, and the higher the activity is; higher numbers after C indicate weaker color development and lower activity; the sign with a "+" after the number is slightly stronger than the non-coloration by 0.5-1C, and the sign with a "-" after the number is slightly lower than the non-coloration by 0.5-1C. B indicates no activity.

As can be seen from the results in Table 8, the antibodies provided in the examples of the present invention have very good detection activity when used in a double antibody sandwich assay on a gold-labeled platform.

The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Sequence listing

<110> Dongguan City of Pengzhi Biotech Co., Ltd

<120> anti-influenza A virus antibody, detection kit and preparation method

<160> 14

<170> SIPOSequenceListing 1.0

<210> 1

<211> 22

<212> PRT

<213> Artificial sequence

<400> 1

Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Phe Leu Trp

1 5 10 15

Arg Val Thr Leu Thr Cys

20

<210> 2

<211> 15

<212> PRT

<213> Artificial sequence

<400> 2

Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Leu Ser

1 5 10 15

<210> 3

<211> 32

<212> PRT

<213> Artificial sequence

<400> 3

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Gln Asp Tyr Ser

1 5 10 15

Leu Thr Ile Ser Ser Leu Glu Tyr Glu Asp Met Gly Ile Tyr Tyr Cys

20 25 30

<210> 4

<211> 12

<212> PRT

<213> Artificial sequence

<400> 4

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg

1 5 10

<210> 5

<211> 25

<212> PRT

<213> Artificial sequence

<400> 5

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln

1 5 10 15

Ser Leu Ser Leu Thr Cys Thr Val Ser

20 25

<210> 6

<211> 14

<212> PRT

<213> Artificial sequence

<400> 6

Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu Gly

1 5 10

<210> 7

<211> 30

<212> PRT

<213> Artificial sequence

<400> 7

Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Leu Glu

1 5 10 15

Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Met Tyr Tyr Cys

20 25 30

<210> 8

<211> 13

<212> PRT

<213> Artificial sequence

<400> 8

Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser

1 5 10

<210> 9

<211> 106

<212> PRT

<213> Artificial sequence

<400> 9

Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln

1 5 10 15

Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr

20 25 30

Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln

35 40 45

Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr

50 55 60

Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg

65 70 75 80

His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro

85 90 95

Ile Val Lys Ser Phe Asn Arg Asn Glu Cys

100 105

<210> 10

<211> 324

<212> PRT

<213> Artificial sequence

<400> 10

Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro Gly Ser Ala

1 5 10 15

Ala Gln Thr Asn Ser Met Val Thr Leu Gly Cys Leu Val Lys Gly Tyr

20 25 30

Phe Pro Glu Pro Val Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser

35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu

50 55 60

Ser Ser Ser Val Thr Val Pro Ser Ser Thr Trp Pro Ser Gln Thr Val

65 70 75 80

Thr Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys

85 90 95

Ile Val Pro Arg Asp Cys Gly Cys Lys Pro Cys Ile Cys Thr Val Pro

100 105 110

Glu Val Ser Ser Val Phe Ile Phe Pro Pro Lys Pro Lys Asp Val Leu

115 120 125

Thr Ile Thr Leu Thr Pro Lys Val Thr Cys Val Val Val Asp Ile Ser

130 135 140

Lys Asp Asp Pro Glu Val Gln Phe Ser Trp Phe Val Asp Asp Val Glu

145 150 155 160

Val His Thr Ala Gln Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr

165 170 175

Phe Arg Ser Val Ser Glu Leu Pro Ile Met His Gln Asp Trp Leu Asn

180 185 190

Gly Lys Glu Phe Lys Cys Arg Val Asn Ser Ala Ala Phe Pro Ala Pro

195 200 205

Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Arg Pro Lys Ala Pro Gln

210 215 220

Val Tyr Thr Ile Pro Pro Pro Lys Glu Gln Met Ala Lys Asp Lys Val

225 230 235 240

Ser Leu Thr Cys Met Ile Thr Asn Phe Phe Pro Glu Asp Ile Thr Val

245 250 255

Glu Trp Gln Trp Asn Gly Gln Pro Ala Glu Asn Tyr Lys Asn Thr Gln

260 265 270

Pro Ile Met Asp Thr Asp Gly Ser Tyr Phe Val Tyr Ser Lys Leu Asn

275 280 285

Val Gln Lys Ser Asn Trp Glu Ala Gly Asn Thr Phe Thr Cys Ser Val

290 295 300

Leu His Glu Gly Leu His Asn His His Thr Glu Lys Ser Leu Ser His

305 310 315 320

Ser Pro Gly Lys

<210> 11

<211> 107

<212> PRT

<213> Artificial sequence

<400> 11

Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Phe Leu Trp

1 5 10 15

Arg Val Thr Leu Thr Cys Lys Ala Ser Gln Asp Leu Asn Gln Tyr Ile

20 25 30

Ser Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Leu Ser

35 40 45

Arg Ala Asn Arg Ile Leu Asp Gly Val Pro Ser Arg Phe Ser Gly Ser

50 55 60

Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Tyr Glu

65 70 75 80

Asp Met Gly Ile Tyr Tyr Cys Ile Gln Tyr Asn Glu Phe Pro Tyr Thr

85 90 95

Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg

100 105

<210> 12

<211> 116

<212> PRT

<213> Artificial sequence

<400> 12

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln

1 5 10 15

Ser Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Ile Thr Ala Tyr

20 25 30

Gly Leu His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu

35 40 45

Gly Leu Ile Trp Gly Gly Gly Ser Thr Asn Tyr Asn Ala Thr Leu Met

50 55 60

Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Leu

65 70 75 80

Glu Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Met Tyr Tyr Cys Ala

85 90 95

Lys Glu Val Thr Gly Arg Met Asp Tyr Trp Gly Gln Gly Thr Ser Val

100 105 110

Thr Val Ser Ser

115

<210> 13

<211> 213

<212> PRT

<213> Artificial sequence

<400> 13

Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Phe Leu Trp

1 5 10 15

Arg Val Thr Leu Thr Cys Lys Ala Ser Gln Asp Leu Asn Gln Tyr Ile

20 25 30

Ser Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Leu Ser

35 40 45

Arg Ala Asn Arg Ile Leu Asp Gly Val Pro Ser Arg Phe Ser Gly Ser

50 55 60

Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Tyr Glu

65 70 75 80

Asp Met Gly Ile Tyr Tyr Cys Ile Gln Tyr Asn Glu Phe Pro Tyr Thr

85 90 95

Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala Pro

100 105 110

Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly

115 120 125

Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn

130 135 140

Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn

145 150 155 160

Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser

165 170 175

Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr

180 185 190

Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe

195 200 205

Asn Arg Asn Glu Cys

210

<210> 14

<211> 440

<212> PRT

<213> Artificial sequence

<400> 14

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln

1 5 10 15

Ser Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Ile Thr Ala Tyr

20 25 30

Gly Leu His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu

35 40 45

Gly Leu Ile Trp Gly Gly Gly Ser Thr Asn Tyr Asn Ala Thr Leu Met

50 55 60

Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Leu

65 70 75 80

Glu Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Met Tyr Tyr Cys Ala

85 90 95

Lys Glu Val Thr Gly Arg Met Asp Tyr Trp Gly Gln Gly Thr Ser Val

100 105 110

Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala

115 120 125

Pro Gly Ser Ala Ala Gln Thr Asn Ser Met Val Thr Leu Gly Cys Leu

130 135 140

Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Val Thr Trp Asn Ser Gly

145 150 155 160

Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Asp

165 170 175

Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro Ser Ser Thr Trp Pro

180 185 190

Ser Gln Thr Val Thr Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys

195 200 205

Val Asp Lys Lys Ile Val Pro Arg Asp Cys Gly Cys Lys Pro Cys Ile

210 215 220

Cys Thr Val Pro Glu Val Ser Ser Val Phe Ile Phe Pro Pro Lys Pro

225 230 235 240

Lys Asp Val Leu Thr Ile Thr Leu Thr Pro Lys Val Thr Cys Val Val

245 250 255

Val Asp Ile Ser Lys Asp Asp Pro Glu Val Gln Phe Ser Trp Phe Val

260 265 270

Asp Asp Val Glu Val His Thr Ala Gln Thr Lys Pro Arg Glu Glu Gln

275 280 285

Phe Asn Ser Thr Phe Arg Ser Val Ser Glu Leu Pro Ile Met His Gln

290 295 300

Asp Trp Leu Asn Gly Lys Glu Phe Lys Cys Arg Val Asn Ser Ala Ala

305 310 315 320

Phe Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Arg Pro

325 330 335

Lys Ala Pro Gln Val Tyr Thr Ile Pro Pro Pro Lys Glu Gln Met Ala

340 345 350

Lys Asp Lys Val Ser Leu Thr Cys Met Ile Thr Asn Phe Phe Pro Glu

355 360 365

Asp Ile Thr Val Glu Trp Gln Trp Asn Gly Gln Pro Ala Glu Asn Tyr

370 375 380

Lys Asn Thr Gln Pro Ile Met Asp Thr Asp Gly Ser Tyr Phe Val Tyr

385 390 395 400

Ser Lys Leu Asn Val Gln Lys Ser Asn Trp Glu Ala Gly Asn Thr Phe

405 410 415

Thr Cys Ser Val Leu His Glu Gly Leu His Asn His His Thr Glu Lys

420 425 430

Ser Leu Ser His Ser Pro Gly Lys

435 440

Claims (10)

1. An antibody against influenza a virus or a functional fragment thereof, comprising the following complementarity determining regions:

CDR-VH 1: G-F-S-X1-T-A-X2-G-X3-H, wherein: x1 is I or L; x2 is F or Y; x3 is L, V or I;

CDR-VH 2: X1-W-X2-G-G-S-T-N-Y-N-X3-T-X4-M-S, wherein: x1 is LL, LI, II or IL; x2 is G or A; x3 is P or A; x4 is L or Y;

CDR-VH 3: A-X1-E-X2-T-G-R-M, wherein: x1 is K or R; x2 is L, V or I;

CDR-VL 1: K-A-S-Q-D-X1-N-X2-Y-X3-S, wherein: x1 is I or L; x2 is Q, R or N; x3 is I, V or L;

CDR-VL 2: R-A-N-R-X1-X2-D, wherein: x1 is I or L; x2 is I, V or L;

CDR-VL 3: X1-Q-Y-X2-E-F-P-Y, wherein: x1 is I, V or L; x2 is N or D.

2. The anti-influenza A virus antibody or functional fragment thereof according to claim 1,

in CDR-VH1, X2 is F;

in CDR-VH2, X2 is A;

in CDR-VH3, X1 is R;

in CDR-VL1, X1 is I;

in CDR-VL2, X1 is L;

in CDR-VL3, X2 is D;

preferably, in CDR-VH1, X1 is I;

preferably, in CDR-VH1, X1 is L;

preferably, in CDR-VH1, X3 is L;

preferably, in CDR-VH1, X3 is V;

preferably, in CDR-VH1, X3 is I;

preferably, in CDR-VH2, X1 is LL;

preferably, in CDR-VH2, X1 is LI;

preferably, in CDR-VH2, X1 is II;

preferably, in CDR-VH2, X1 is IL;

preferably, in CDR-VH2, X3 is P;

preferably, in CDR-VH2, X3 is A;

preferably, in CDR-VH2, X4 is L;

preferably, in CDR-VH2, X4 is Y;

preferably, in CDR-VH3, X2 is L;

preferably, in CDR-VH3, X2 is V;

preferably, in CDR-VH3, X2 is I;

preferably, in CDR-VL1, X2 is Q;

preferably, in CDR-VL1, X2 is R;

preferably, in CDR-VL1, X2 is N;

preferably, in CDR-VL1, X3 is I;

preferably, in CDR-VL1, X3 is V;

preferably, in CDR-VL1, X3 is L;

preferably, in CDR-VL2, X2 is I;

preferably, in CDR-VL2, X2 is V;

preferably, in CDR-VL2, X2 is L;

preferably, in CDR-VL3, X1 is I;

preferably, in CDR-VL3, X1 is V;

preferably, in CDR-VL3, X1 is L;

preferably, each complementarity determining region of the antibody or functional fragment thereof is selected from any one of the following combinations of mutations 1-62:

3. the anti-influenza a virus antibody or functional fragment thereof of claim 2, wherein the antibody or functional fragment thereof binds to an influenza a virus antigen as K_D≤4.4×10^-8Affinity binding of mol/L; preferably, K_D≤8.47×10^-9mol/L。

4. The anti-influenza A virus antibody or functional fragment thereof according to claim 1,

in CDR-VH1, X2 is Y;

in CDR-VH2, X2 is G;

in CDR-VH3, X1 is K;

in CDR-VL1, X1 is L;

in CDR-VL2, X1 is I;

in CDR-VL3, X2 is N;

preferably, each complementarity determining region of the antibody or functional fragment thereof is selected from any one of the following combinations of mutations 63-70:

5. the anti-influenza a virus antibody or functional fragment thereof according to any one of claims 1 to 4, wherein the antibody comprises light chain framework regions FR1-L, FR2-L, FR3-L and FR4-L in sequence as shown in SEQ ID NOs 1 to 4, and/or heavy chain framework regions FR1-H, FR2-H, FR3-H and FR4-H in sequence as shown in SEQ ID NOs 5 to 8;

preferably, the antibody further comprises a constant region;

preferably, the constant region is selected from the constant regions of any one of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE and IgD;

preferably, the species of the constant region is from a cow, horse, cow, pig, sheep, goat, rat, mouse, dog, cat, rabbit, camel, donkey, deer, mink, chicken, duck, goose, turkey, chicken fight, or human;

preferably, the constant region is derived from a mouse;

preferably, the light chain constant region sequence of the constant region is shown as SEQ ID NO. 9, and the heavy chain constant region sequence of the constant region is shown as SEQ ID NO. 10;

preferably, the functional fragment is selected from any one of VHH, F (ab ') 2, Fab', Fab, Fv and scFv of the antibody.

6. A reagent or kit for detecting influenza a virus comprising the antibody or functional fragment thereof according to any one of claims 1 to 5.

7. The reagent or kit according to claim 6, wherein the antibody or functional fragment thereof is labeled with a detectable label;

preferably, the detectable label is selected from the group consisting of a fluorescent dye, an enzyme that catalyzes the color development of a substrate, a radioisotope, a chemiluminescent reagent, and a nanoparticle-based label;

preferably, the fluorescent dye is selected from fluorescein dyes and derivatives thereof, rhodamine dyes and derivatives thereof, Cy dyes and derivatives thereof, Alexa dyes and derivatives thereof, and protein dyes and derivatives thereof;

preferably, the enzyme catalyzing the color development of the substrate is selected from the group consisting of horseradish peroxidase, alkaline phosphatase, beta-galactosidase, glucose oxidase, carbonic anhydrase, acetylcholinesterase, and glucose-6-phosphate deoxyenzyme;

preferably, the radioisotope is selected from the group consisting of²¹²Bi、¹³¹I、¹¹¹In、⁹⁰Y、¹⁸⁶Re、²¹¹At、¹²⁵I、¹⁸⁸Re、¹⁵³Sm、²¹³Bi、³²P、⁹⁴mTc、⁹⁹mTc、²⁰³Pb、⁶⁷Ga、⁶⁸Ga、⁴³Sc、⁴⁷Sc、¹¹⁰mIn、⁹⁷Ru、⁶²Cu、⁶⁴Cu、⁶⁷Cu、⁶⁸Cu、⁸⁶Y、⁸⁸Y、¹²¹Sn、¹⁶¹Tb、¹⁶⁶Ho、¹⁰⁵Rh、¹⁷⁷Lu、¹⁷²Lu and¹⁸F；

preferably, the chemiluminescent reagent is selected from luminol and its derivatives, lucigenin, crustacean fluorescein and its derivatives, bipyridine ruthenium and its derivatives, acridinium ester and its derivatives, dioxetane and its derivatives, lowhine and its derivatives, and peroxyoxalate and its derivatives;

preferably, the nanoparticle-based label is selected from the group consisting of nanoparticles, colloids, organic nanoparticles, magnetic nanoparticles, quantum dot nanoparticles, and rare earth complex nanoparticles;

preferably, the colloid is selected from the group consisting of colloidal metals, disperse dyes, dye-labeled microspheres, and latexes;

preferably, the colloidal metal is selected from the group consisting of colloidal gold, colloidal silver and colloidal selenium.

8. A vector comprising a nucleic acid molecule encoding the antibody or functional fragment thereof according to any one of claims 1-5.

9. A recombinant cell comprising the vector of claim 8.

10. A method for producing an antibody or functional fragment thereof according to any one of claims 1 to 5, comprising: culturing the recombinant cell of claim 9, and isolating and purifying the antibody or functional fragment thereof from the culture product.

Images